Results 71 to 80 of about 36,030 (253)

Adaptation of the REINVENT neural network architecture to generate potential HIV-1 entry inhibitors

Informatika
Objectives. The main purpose of this work is to adapt the architecture of the REINVENT neural network to generate potential inhibitors of the HIV-1 envelope protein gp120 using in the learning process with reinforcement of molecular docking on GPUs ...
D. A. Varabyeu, A. D. Karpenko, A. V. Tuzikov, A. M. Andrianov   +3 more
doaj   +1 more source

HIV induces synaptic hyperexcitation via cGMP-dependent protein kinase II activation in the FIV infection model.

PLoS Biology, 2018
Over half of individuals infected with human immunodeficiency virus (HIV) suffer from HIV-associated neurocognitive disorders (HANDs), yet the molecular mechanisms leading to neuronal dysfunction are poorly understood. Feline immunodeficiency virus (FIV)
Keira Sztukowski, Kaila Nip, Paige N Ostwald, Matheus F Sathler, Julianna L Sun, Jiayi Shou, Emily T Jorgensen, Travis E Brown, John H Elder, Craig Miller, Franz Hofmann, Sue VandeWoude, Seonil Kim   +12 more
doaj   +1 more source

Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters

BMC Immunology, 2006
Background One of the major obstacles in the design of an effective vaccine against HIV-1 is the hypervariability of the HIV-1 envelope glycoprotein. Most HIV-1 vaccine candidates have utilized envelope glycoprotein from a single virus isolate, but to ...
Ghorbani Masoud, Anderson David E, Azizi Ali, Gee Katrina, Diaz-Mitoma Francisco   +4 more
doaj   +1 more source

A saposin-lipoprotein nanoparticle system for membrane proteins. [PDF]

, 2016
A limiting factor in membrane protein research is the ability to solubilize and stabilize such proteins. Detergents are used most often for solubilizing membrane proteins, but they are associated with protein instability and poor compatibility with ...
Armache, Jean-Paul, Briggs, John AG, Cheng, Yifan, Flayhan, Ali, Frauenfeld, Jens, Garoff, Henrik, Guettou, Fatma, Jegerschöld, Caroline, Löving, Robin, Löw, Christian, Moberg, Per, Nordlund, Pär, Sonnen, Andreas F-P, Zhu, Lin   +13 more
core   +2 more sources

Chimera X Interface to Enhance Understanding in Biochemistry and Immunology

Biochemistry and Molecular Biology Education, Volume 54, Issue 1, Page 92-102, January/February 2026.
ABSTRACT Proteins are essential in biological systems, acting in transport, catalysis, and immune defense processes. However, these biomolecules' structural and functional complexity makes teaching and understanding these topics challenging. To address this difficulty, this study aimed to develop tutorials that facilitate learning and teaching about ...
Dalpiaz Giovana, Krohn Muriel Schiling, Groehs Eduarda, Anjos André da Silva, Meireles R. Mariana   +4 more
wiley   +1 more source

Sequence-Conserved and Antibody-Accessible Sites in the V1V2 Domain of HIV-1 gp120 Envelope Protein [PDF]

AIDS Research and Human Retroviruses, 2014
The immune-correlates analysis of the RV144 trial suggested that epitopes targeted by protective antibodies (Abs) reside in the V1V2 domain of gp120. We mapped V1V2 positional sequence variation onto the conserved V1V2 structural fold and showed that while most of the solvent-accessible V1V2 amino acids vary between strains, there are two accessible ...
Shmelkov, Evgeny, Grigoryan, Arsen, Krachmarov, Chavdar, Abagyan, Ruben, Cardozo, Timothy   +4 more
openaire   +4 more sources

The Prefusogenic Intermediate of HIV-1 gp41 Contains Exposed C-peptide Regions [PDF]

, 2003
The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein is composed of a complex between the surface subunit gp120, which binds to cellular receptors, and the transmembrane subunit gp41.
Chan, David C., Koshiba, Takumi
core  

Chimeric Antigen Receptor T‐Cell Therapy: More Than an Anti‐Cancer Drug

HLA, Volume 107, Issue 1, January 2026.
ABSTRACT Initially, chimeric antigen receptor (CAR) T‐cell therapy was developed to eliminate malignant B cells in haematological B‐cell malignancies by targeting CD19 and B‐cell maturation antigen. This approach achieved notable success, resulting in (malignant) B‐cell depletion and inducing clinical remission in cancer patients.
Hannah C. M. Schenk, Ilse Gille, Carolt Arana, Jordi Rovira, Eduard Palou, Fritz Diekmann, Dave L. Roelen, Mirjam H. M. Heemskerk, Sebastiaan Heidt   +8 more
wiley   +1 more source

Helix-A peptide prevents gp120-mediated neuronal loss

Molecular Brain, 2019
Aim The human-immunodeficiency virus (HIV) envelope protein gp120 promotes synaptic damage similar to that observed in people living with HIV who have neurocognitive disorders.
Valeria Avdoshina, Francesca Taraballi, Ennio Tasciotti, Aykut Üren, Italo Mocchetti   +4 more
doaj   +1 more source

Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV

npj Vaccines, 2022
Since publishing our original reports on the safety and immunogenicity of a polyvalent DNA prime-protein boost HIV vaccine (PDPHV) which elicited high titer antibody responses with broad specificity, neutralizing activities to multiple HIV-1 subtypes, as
Shixia Wang, Nicole L. Yates, Justin Pollara, Yegor Voronin, Sherry Stanfield-Oakley, Dong Han, Guangnan Hu, Wei Li, Guido Ferrari, Georgia D. Tomaras, Shan Lu   +10 more
doaj   +1 more source